European Archives - Page 1079 of 1137 - European Medical Journal

EMJ

New Tool Completes Skin Biopsies in Minutes Without Anaesthetic

SKIN biopsy technology has taken a leap forward thanks to a new device that requires fewer instruments, which researchers promise will reduce the time…

EMJ

1 in 5 Young VTE Patients Require Psychotropic Drugs within 5 Years

Dubrovnik, Croatia – 14 June 2015: One in five young people who experience a venous thromboembolism (VTE)1 will require psychotropic medication…

EMJ

Asthma Treatment Breakthrough Brings Hope to Millions

ASTHMA sufferers worldwide could soon benefit from the results of a ground-breaking study conducted by Cardiff University, Cardiff, UK, which has…

EMJ

3D-Printed Implants Save Lives of Babies with Tracheobronchomalacia

THREE babies suffering from an airway condition that presented little chance of them reaching young childhood have had their lives saved by…

EMJ

The Last Frontier, Men’s Health

The 21st century is well upon us, and the scientific and health landscape is rapidly changing, yet there are still new horizons to conquer.

EMJ

Dr Kevin Campbell, Our #EMJExpert, Answers Your Questions for Heart Rhythm Week

In support of Heart Rhythm Week, an annual campaign designed to raise global awareness and understanding of arrhythmias, we invited world-renowned…

EMJ

Early-Stage Trial of Nivolumab in Advanced Liver Cancer

Findings from a phase I/II study suggest that nivolumab is safe and effective in advanced liver cancer. Based on the results of the phase I part of the…

EMJ

Genomic Marker Predicts Anti-PD-1 Response in Several Cancers

A phase II study identified the first genomic marker – mismatch repair (MMR) deficiency – to predict response to the anti-PD-1 antibody pembrolizumab…

EMJ

Pembrolizumab Shows Promising Activity Against Head and Neck Cancer

A 132-patient study indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC). The…

EMJ

Nivolumab Extends Survival for Patients With the Most Common Lung Cancer

Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small…